Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in high-impact areas.

The Johnson & Johnson JNJ stock has risen 4.4% in six months, adding more than $15 billion to its market value. J&J faces ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated ...

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to data presented at the 2025 Society for Investigative Dermatology Annual ...

Icotrokinra is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of plaque psoriasis and other IL-23 mediated diseases.

Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill. SPRING HOUSE, Pa., ...

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almos Tuesday, 02 January 2024 12:17 GMT عربي ...

Icotrokinra demonstrated a favorable safety profile. A similar proportion of patients experienced adverse events (50% and 42%) and serious adverse events (0.5% and 1.9%) ...

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to ...